A global investment firm agreed to acquire a medical device maker for $5.7 billion, while Juvisé Pharmaceuticals secured a $652 million refinancing and Pharmacelera raised $7.1 million. A biotech company also completed a $289 million IPO, and the MHRA issued AI guidance.
Aldeyra Therapeutics announced CEO Dr. Todd Brady will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, in New York. The live webcast will be available on the company's website and archived for 90 days. Aldeyra is a biotechnology company focused on therapies for immune-mediated diseases.
Johnson & Johnson invests over $1 billion in a new Pennsylvania cell therapy manufacturing facility for cancer and neurological diseases. The expansion addresses growing demand for advanced therapies while highlighting workforce training challenges in GMP environments. Other developments include new cell line technology for viral vector production and CRISPR-edited CAR-T manufacturing partnerships.
Johnson & Johnson announced a $1 billion cell therapy manufacturing facility in Pennsylvania while reportedly exploring a sale of its DePuy Synthes orthopedics business for over $20 billion.
Long-term data from the QUASAR extension study show TREMFYA® maintained clinical remission in over 80% of ulcerative colitis patients at Week 140, with more than half achieving endoscopic remission and no new safety concerns observed.
Johnson & Johnson announced plans to invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, expected to create 500 jobs when fully operational in 2031.
Johnson & Johnson announced plans to invest over $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, creating 500 biomanufacturing jobs as part of its $55 billion U.S. expansion commitment through 2029.
Johnson & Johnson announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, part of the company's $55 billion U.S. investment strategy through early 2029.
The Phase III MAJESTY study met its primary endpoint, showing significantly more people achieved complete remission at two years with Gazyva versus tacrolimus. If approved, Gazyva would be the first therapy specifically indicated for primary membranous nephropathy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07033663 |
Impact of In Utero Exposure to Immunomodulatory Drugs on Neonatal Immune System Development |
RECRUITING | |
| NCT06753942 |
ANTI-SARS-CoV-2 SEROCONVERSIO IN IMMUNE-MEDIATED KIDNEY DISEASES |
COMPLETED | |
| NCT04864886 |
Metabolic Profiling of Immune Responses in Immune-mediated Diseases |
RECRUITING |
